Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 24.
doi: 10.1002/mdc3.70239. Online ahead of print.

Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

Diego Santos-García  1   2   3   4 , Ángela Solleiro  2 , Guillermo González-Ortega  5 , Pablo Mir  6   7   8 , Nuria López-Ariztegui  9 , Rocío García Ramos  10 , Inés Legarda  11 , Anna Planas-Ballvé  12 , Deborah Alonso-Modino  13 , Pilar Sánchez-Alonso  14 , Iria Cabo  15 , Marta Blázquez-Estrada  16 , Álvaro Sánchez-Ferro  7   17 ; DATs‐PD GETM Spanish Registry Group
Collaborators, Affiliations

Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

Diego Santos-García et al. Mov Disord Clin Pract. .

Abstract

Background and objective: New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024.

Patients and methods: Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.

Results: A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.

Conclusion: Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.

Keywords: Parkinson's disease; deep brain stimulation; device‐aided therapies; infusion; registry; subcutaneous.

PubMed Disclaimer

References

    1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397:2284–2303.
    1. Tanner CM, Ostrem JL. Parkinson's disease. N Engl J Med 2024;391:442–452.
    1. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756–1760.
    1. Foltynie T, Bruno V, Fox S, Kühn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet 2024;403:305–324.
    1. Deuschl G, Antonini A, Costa J, et al. European academy of neurology/Movement Disorder Society‐European section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Mov Disord 2022;37:1360–1374.

LinkOut - more resources